Sigma Pharmaceuticals

When new management took control of drug wholesaler Sigma Pharmaceuticals in 2010, the company was in poor shape (see Sigma returns to its roots from 17 Aug 10 (Ceasing coverage – $0.49)). It’s testament to management’s ability that the company has emerged stronger despite numerous setbacks. Sigma’s management has addressed some important issues over the past three years, despite the collapse of a major customer, further government-mandated cuts to medicine prices under the Pharmaceutical Benefits Scheme, and the direct-to-pharmacy sales approach adopted by Pfizer. The company has tightened trading terms to its pharmacy customers, reduced investment in working capital,...

When new management took control of drug wholesaler Sigma Pharmaceuticals in 2010, the company was in poor shape (see Sigma returns to its roots from 17 Aug 10 (Ceasing coverage – $0.49)). It’s testament to management’s ability that the company has emerged stronger despite numerous setbacks.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles